The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...
Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA ...
Yuvezzi, a combination cholinergic agonist and alpha-adrenergic agonist, is now FDA-approved as a once-daily treatment for ...
The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics. Yuvezzi ...
Tenpoint Therapeutics announced FDA’s approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% ...
YUVEZZI (TM) (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a ...
The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...
The FDA approved carbachol/brimonidine tartrate ophthalmic solution (Yuvezzi) for adults with presbyopia, marking the first ...
MedPage Today on MSN
FDA OKs More Eye Drops That Can Replace Reading Glasses
Once-daily carbachol/brimonidine tartrate significantly improves aging-related vision loss ...
Please provide your email address to receive an email when new articles are posted on . The submission is supported by positive data from the phase 3 BRIO-I and BRIO-II studies. If approved, Brimochol ...
Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results